Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 5/20 | 0.69 |
| ▸ | MGLL | Q99685 | 4/20 | 0.69 |
| ▸ | TRAP1 | Q12931 | 5/20 | 0.56 |
| ▸ | HSP90B1 | P14625 | 4/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31014031 | 0.92 | ESR2 (0.62) | ABHD6MGLLTRAP1HSP90B1ESR2 | |
| SCHEMBL31013888 | 0.92 | NR1H2 (0.61) | ABHD6MGLLTRAP1HSP90B1ESR2 | |
| SCHEMBL12708169 | 0.88 | ABHD6 (0.54) | ABHD6MGLLTRAP1HSP90B1ESR2 | |
| SCHEMBL5100452 | 0.88 | ESR2 (0.60) | ABHD6MGLLTRAP1HSP90B1ESR2 | |
| SCHEMBL24761833 | 0.86 | ABHD6 (0.55) | ABHD6MGLLESR2NR1H2HDAC1 | |
| SCHEMBL23259007 | 0.86 | ABHD6 (0.52) | ABHD6MGLLESR2NR1H2HDAC1 | |
| SCHEMBL14959463 | 0.86 | ABHD6 (0.70) | ABHD6MGLLTRAP1HSP90B1HSP90AA1 | |
| SCHEMBL3875946 | 0.86 | ABHD6 (0.57) | ABHD6MGLLESR2NR1H2HDAC1 | |
| SCHEMBL3877051 | 0.85 | ABHD6 (0.51) | ABHD6MGLLESR2NR1H2HDAC1 | |
| SCHEMBL11936442 | 0.85 | ABHD6 (0.69) | ABHD6MGLLTRAP1HSP90B1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651955-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| WO-2024153947-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2024-07-25 | — | — | WO | disclosed |
| US-11312722-B2 | Hsp90 inhibitors and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2020227368-A1 | HSP90 INHIBITORS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20200354373-A1 | HSP90 INHIBITORS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-11-12 | — | — | US | disclosed |
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-8445527-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-09-13 | — | — | US | disclosed |
| US-8211932-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2012-07-03 | — | — | US | disclosed |
| EP-2155690-B1 | INDAZOLAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-12-30 | — | — | US | disclosed |
| US-7825152-B2 | serine protease inhibitors, for the treatment of hepatitis c virus infections | NOVARTIS AG (CH) | 2010-11-02 | — | — | US | disclosed |
| US-7825152-B2 | serine protease inhibitors, for the treatment of hepatitis c virus infections | NOVARTIS AG (CH) | 2010-11-02 | — | — | US | disclosed |
| US-20100256137-A1 | INDAZOLAMIDE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-10-07 | — | — | US | disclosed |
| US-20100256137-A1 | INDAZOLAMIDE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-10-07 | — | — | US | disclosed |
| US-20100256137-A1 | INDAZOLAMIDE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-10-07 | — | — | US | disclosed |
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| WO-2008155001-A1 | INDAZOLAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-12-24 | — | — | WO | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070286842-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331243-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | ABHD6 1888/4885MGLL 1493/4885TRAP1 901/4885 |
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | ABHD6 3334/4885MGLL 748/4885TRAP1 2586/4885 |
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, HAVCR2, CPT1A | ABHD6 1766/4885MGLL 574/4885TRAP1 2345/4885 |
| US-20070286842-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | ABHD6 1888/4885MGLL 1493/4885TRAP1 901/4885 |
| US-20200354373-A1 | HSP90 INHIBITORS AND USES THEREOF | HSP90AB1, HSP90B1, HSP90AA1 | ABHD6 3246/4885MGLL 2889/4885TRAP1 8/4885 |
| US-20100256137-A1 | INDAZOLAMIDE DERIVATIVES | HSP90AB1, HSP90AA1, HSP90AB2P | ABHD6 3974/4885MGLL 4573/4885TRAP1 29/4885 |
| US-11312722-B2 | Hsp90 inhibitors and uses thereof | HSP90AB1, HSP90B1, HSP90AA1 | ABHD6 3246/4885MGLL 2889/4885TRAP1 8/4885 |
| US-20120231998-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | ABHD6 1888/4885MGLL 1493/4885TRAP1 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.